COMMUNIQUÉS West-GlobeNewswire

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
27/02/2025
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline [...]
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
27/02/2025
REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a [...]
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
27/02/2025
Commercial Preparations On-Track Ahead of September 25, 2025 PDUFA Date Including Regulatory Review Process, Organizational Build, and Key Stakeholder Engagement Efforts Expecting to Initiate Four Late-Stage Trials and [...]
Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results
27/02/2025
— Record revenues of $701 million in 2024 — — Full-year GAAP net loss of $100 million and adjusted EBITDA of $224 million — — Conference call today at 4:30 p.m. ET — PARSIPPANY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- [...]
Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook
27/02/2025
Validated technology with exceptional growth of customer publications and enhanced access to the Proteograph Product Suite with growing demand for Seer Technology Access Center (STAC) REDWOOD CITY, Calif., Feb. 27, 2025 [...]
Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook
27/02/2025
FREMONT, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth [...]
Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress
27/02/2025
Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2 VTX3232 in participants with obesity and cardiometabolic risk factors in H2 VTX3232 [...]
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights
27/02/2025
Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)- [...]
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024
27/02/2025
Reshaping its Board of Directors at the upcoming Shareholders’ meeting with the aim of enhancing U.S. outreach Preparations for PORTICO-2 Phase III trial with vafidemstat in agitation/aggression in Borderline [...]
NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award
27/02/2025
TORONTO and HAIFA, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that it has been selected to present at [...]
Progyny, Inc. Announces Fourth Quarter 2024 Results
27/02/2025
Reports Quarterly Revenue of $298.4 Million, Reflecting 10.6% Growth Generated $52.2 Million of Quarterly Operating Cash Flow Issues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Revenue Growth NEW [...]
Standard BioTools to Participate in Upcoming Investor Conferences
27/02/2025
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences: TD Cowen’s 45th Annual [...]
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024
27/02/2025
Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M Reaffirming FY25 Total Product Revenue [...]
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
27/02/2025
Enrollment ongoing in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under development Phase 2 barzolvolimab EOE study fully accrued; Phase 2 study initiated in atopic dermatitis; enrollment ongoing in [...]
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update
27/02/2025
– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD studies underway, with second [...]
WW International, Inc. Announces Fourth Quarter and Full Year 2024 Results
27/02/2025
Fourth Quarter 2024 Financial Highlights Total End of Period Subscribers of 3.3 million, including 92 thousand End of Period Clinical Subscribers Revenues of $184.4 million; Subscription Revenues down 7.3% vs. prior [...]
Alignment Healthcare Reports Fourth Quarter and Full-Year 2024 Results; Provides Full-Year 2025 Financial Guidance
27/02/2025
Reports 189,100 health plan members as of Dec. 31, 2024, up 58.6% year-over-year, beating year-end expectations Achieves first full year of positive adjusted EBITDA as a public company, driven by operating leverage and [...]
Amedisys Reports Fourth Quarter and Year End 2024 Financial Results
26/02/2025
BATON ROUGE, La., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2024. Three-Month Periods Ended December 31, [...]
Rapid Micro Biosystems to Participate in Upcoming Investor Conferences
26/02/2025
LEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]

Pages